Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ

被引:50
作者
Jun, JB
Kuechle, M
Min, J
Shim, SC
Kim, G
Montenegro, V
Korn, JH
Elkon, KB [1 ]
机构
[1] Univ Washington, Sch Med, Div Rheumatol, Seattle, WA 98104 USA
[2] Univ Washington, Sch Med, Div Dermatol, Seattle, WA 98104 USA
[3] Boston Univ, Sch Med, Div Rheumatol, Boston, MA USA
关键词
Akt; apoptosis; fibroblast; scleroderm;
D O I
10.1111/j.0022-202X.2004.23559.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Recent studies suggest that, in addition to activation and hypersecretion of matrix components, fibroblasts from patients with systemic sclerosis (SSc) are relatively resistant to apoptosis. Transforming growth factor-beta (TGF)-beta is strongly implicated in the pathogenesis of SSc and we and others have shown that TGF-beta can activate Akt, a kinase with potent anti-apoptotic effects. To determine whether Akt was activated in SSc, we quantified phospho-Akt expression in skin fibroblasts in vitro by western blot analysis and a functional kinase assay. In addition, the relative proportion of fibroblasts containing activated Akt in was quantified by immunohistochemistry on skin sections in situ. Analysis of Akt phosphorylation of skin fibroblasts in vitro suggested increased phosphorylation of Akt, and evaluation of skin sections by immunohistochemistry revealed significantly higher percentages of fibroblasts that stained for phospho-Akt compared with controls (78% +/- 14.0% vs 13% +/- 9%, p < 0.001). In addition, co-incident staining of phospho-Akt and alpha-smooth muscle actin was observed in some fibroblasts. These findings indicate that Akt is activated in situ in skin fibroblasts from patients with SSc. Akt activation may contribute to resistance to apoptosis, selection of disease-inducing fibroblasts, and, possibly, myofibroblasts.
引用
收藏
页码:298 / 303
页数:6
相关论文
共 52 条
[41]   TRANSFORMING GROWTH-FACTOR TYPE-BETA - RAPID INDUCTION OF FIBROSIS AND ANGIOGENESIS INVIVO AND STIMULATION OF COLLAGEN FORMATION INVITRO [J].
ROBERTS, AB ;
SPORN, MB ;
ASSOIAN, RK ;
SMITH, JM ;
ROCHE, NS ;
WAKEFIELD, LM ;
HEINE, UI ;
LIOTTA, LA ;
FALANGA, V ;
KEHRL, JH ;
FAUCI, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (12) :4167-4171
[42]  
ROBERTS AB, 2001, SCI STKE, pE43
[43]  
Santiago B, 2001, ARTHRITIS RHEUM-US, V44, P1667, DOI 10.1002/1529-0131(200107)44:7<1667::AID-ART291>3.0.CO
[44]  
2-Y
[45]   Transforming growth factor β enhances epithelial cell survival via Akt-dependent regulation of FKHRL1 [J].
Shin, I ;
Bakin, AV ;
Rodeck, U ;
Brunet, A ;
Arteaga, CL .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (11) :3328-3339
[46]  
SIME PJ, 1991, CLIN IMMUNOL, V99, P306
[47]   Cytokine directed therapy in scleroderma: rationale, current status, and the future [J].
Simms, RW ;
Korn, JH .
CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (06) :717-722
[48]  
TROJANOWSKA M, 1988, ONCOGENE, V3, P477
[49]   Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach [J].
Verrecchia, F ;
Chu, ML ;
Mauviel, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (20) :17058-17062
[50]   Transforming growth factor β1 (TGF-PI) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling [J].
Vinals, F ;
Pouysségur, J .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (21) :7218-7230